Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Fecal microbiota transplantation (FMT) has been shown to be a superior therapeutic modality for the treatment of recurrent Clostridium difficile infection (RCDI). Recently the US Food and Drug Administration (FDA) determined that human stool should be classified as a biological agent and its use should be regulated to ensure patient safety. Consequently, the FDA determined that prescribers of FMT must possess an approved investigational new drug (IND) permit to administer FMT for the purpose of conducting research or treating any gastrointestinal condition other than RCDI. Although an IND is not required for use of FMT to treat RCDI, an IND is strongly encouraged and may ultimately be required. This article provides step-by-step guidance to infectious disease specialists on how to navigate the regulatory requirements and successfully obtain an IND before they can begin to use FMT as part of their clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent abstract reporting a survey of physicians showed that 40% were not willing to try FMT, pending further demonstration of its efficacy, safety and perceived patient acceptance.116”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [116]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 2×
“Most recently, an open-label, randomized, controlled trial directly comparing FMT with two different antibiotic regimens clearly demonstrated the superiority of FMT in patients with recurrent CDI” [7].”
BackgroundResultTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 2×
“Details regarding donor selection, screening, sample preparation, and administration details have been published previously and are not reviewed here [9, 11].”
BackgroundSelf-citation(1958) · PubMed · Cited by 978
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731 · cited 2×
“case series [9, 12] in patients with recurrent CDI resulting in superior cure rates compared to previously reported cure rates with standard therapy.”
BackgroundResultGerding, D. N. (1986) · Archives of Internal Medicine · doi:10.1001/archinte.1986.00360130117016 · Cited by 370
Miller, B. A., Chen, L. F., Sexton, D. J., & Anderson, D. J. (2011) · Infection Control & Hospital Epidemiology · doi:10.1086/659156 · Cited by 350 · cited 5×
“The website will contain online links to FDA forms 1571, 1572, and 3674; FMT protocol; and informed consent templates as well as a geographical map of FMT provider sites with contact information throughout the United States and Canada.”
BackgroundInfluentialEconomic healthcare costs of Clostridium difficile infection: a systematic review
Ghantoji, S. S., Sail, K., Lairson, D. R., DuPont, H. L., & Garey, K. W. (2010) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.10.016 · Cited by 288 · cited 1×
“associated deaths [2, 3] and annual costs exceeding $1 billion [4].”
BackgroundFecal bacteriotherapy for recurrent Clostridium difficile infection
Bakken, J. S. (2009) · Anaerobe · doi:10.1016/j.anaerobe.2009.09.007 · Cited by 218 · cited 4×
“Details regarding donor selection, screening, sample preparation, and administration details have been published previously and are not reviewed here [9, 11].”
BackgroundMethodResultInfluentialSelf-citationSchwartz, M., Gluck, M., & Koon, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.164 · Cited by 162 · cited 1×
“with FMT, including those not yet reported (eg, intestinal perforation, sepsis, transmission of an infectious agent from the donor stool [13]).”
BackgroundRubin, T. A., Gessert, C. E., Aas, J., & Bakken, J. (2012) · Anaerobe · doi:10.1016/j.anaerobe.2012.11.004 · Cited by 142 · cited 1×
“excess of 90%, with a negligible significant adverse event rate, regardless of route [10].”
BackgroundSelf-citation
Research works printed but not linked: 4
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
- Eiseman, 1958, Surgery, 44, 854
- 2012, 19, 22
- 2013, The American journal of gastroenterology, 108, 1367
Cited by
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Self-citationFecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O. G., Beaulieu, D. B., & Acra, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub2 · Cited by 164
“The short and long term safety of FMT in patients with IBD is not well established (Cammarota 2017; Kelly 2015; Moore 2014).”
BackgroundMethodInfluentialEffects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways
Chen, J., Zhao, K.-N., & Vitetta, L. (2019) · Nutrients · doi:10.3390/nu11051026 · Cited by 198
Fischer, M., Sipe, B., Cheng, Y.-W., Phelps, E., Rogers, N., Sagi, S., Bohm, M., Xu, H., & Kassam, Z. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1273998 · Cited by 192
“The adoption of FMT by clinicians was hampered by logistics of preparation and complexity as well as cost of donor screening.(57) Universal stool banks emerged to ensure universal access to FMT and enable clinicians to treat CDI patients both effectively and safely.”
BackgroundHow to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
Metadata
- Authors
- Moore, T., Rodriguez, A., & Bakken, J. S.
- Affiliations
- Infectious Diseases Society of America (US)
- St. Luke's Hospital (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-23
- Volume
- 58
- Issue
- 4
- Pages
- 541-545
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2111426729
- Cited by
- 69
- References
- 13
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 9 · 2014: 13
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American College of Gastroenterology
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, FDA regulation, regulatory requirements, patient safety
- MeSH terms
- Biological Therapy, Feces, Gastrointestinal Diseases, Humans, United States, Drugs, Investigational, Investigational New Drug Application
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist. https://app.cochat.ai/papers/10.1093/cid/cit950
- The paper
- Moore, T., Rodriguez, A., & Bakken, J. S. (2014). Fecal Microbiota Transplantation: A Practical Update for the Infectious Disease Specialist. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cit950
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.